Rationale and design of the HINODE study: Heart failure indication and sudden cardiac death prevention trial Japan

• Published in: Journal of arrhythmia 2021-08, Vol.37 (4), p.1031-1037
• Main Authors: Yamasaki, Hiro, Ando, Kenji, Ikeda, Takanori, Mitsuhashi, Takeshi, Murohara, Toyoaki, Nishii, Nobuhiro, Nogami, Akihiko, Sakata, Yasushi, Shimizu, Wataru, Simon, Torri, Beaudoint, Caroline, Kayser, Torsten, Kutyifa, Valentina, Aonuma, Kazutaka
• Format: Article
• Language: English
• Subjects: Angioplasty; Arrhythmia; Cardiac arrest; Cardiac arrhythmia; Cardiology; Care and treatment; Clinical trials; Creatinine; defibrillator therapy; Defibrillators; Diabetes; Ejection fraction; Enrollments; Enzymes; Health aspects; Heart; Heart attacks; Heart failure; Heart rate; Heart surgery; Implants, Artificial; Informed consent; Japan; Life expectancy; Mortality; Original; Pacemakers; Patients; Prevention; Prosthesis; resynchronization therapy; Risk factors; sudden cardiac death
• ISSN: 1880-4276; 1883-2148
• DOI: 10.1002/joa3.12577

Background Randomized trials in Western countries have provided evidence that prophylactic implantable cardioverter‐defibrillator (ICD) therapy reduces mortality in heart failure (HF) patients with reduced left ventricular ejection fraction. However, the risk of life‐threatening ventricular arrhythmias in Japanese HF patients sharing similar risk factors is still unknown. Methods The Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan trial (NCT03185832) is a prospective, multicenter registry designed to collect data on ventricular arrhythmia, HF events, and mortality in Japanese HF patients. Japanese patients with HF and 2‐5 predefined risk factors who were indicated for cardiac device implantation based on European Society of Cardiology guidelines were enrolled in four treatment arms: implantable cardioverter‐defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT‐D), HF pacing (PA; Pacemaker and cardiac resynchronization pacemaker), and nondevice (ND) cohorts and followed for a minimum of 12 months. Since it is anticipated that some baseline patient characteristics and risk factors will differ significantly from those reported in predominantly Western populations, event rates will be compared to a propensity‐matched population from the MADIT RIT trial. Primary endpoints are composite rates of first appropriately treated ventricular arrhythmias (VA) or/and life‐threatening VA symptoms for the ICD and CRT‐D cohorts. For nondevice and PA cohorts, the primary outcome is all‐cause mortality. Conclusions The Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan is a large prospective multicenter registry with defined device treatment cohorts and will provide data for risk stratification for cardiovascular events in Japanese HF patients.